ANIMAX LIMITED – Trademark Portfolio

Entity Type: 03

ANIMAX LIMITED holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include COPASURE and TRACESURE. The owner is based in SUFFOLK.

SHEPHERDS GROVE WEST

STANTON, BURY ST. EDMONDS

SUFFOLK IP31 2A , GB

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

ANIMAX LIMITED's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

31
Natural Agricultural Products (2 filings)

Raw and unprocessed agricultural, aquacultural, horticultural and forestry products

Frequently Asked Questions

How many trademarks does ANIMAX LIMITED have?

ANIMAX LIMITED has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned, 2 cancelled.

What trademark classes does ANIMAX LIMITED file in?

ANIMAX LIMITED files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are ANIMAX LIMITED's most well-known trademarks?

ANIMAX LIMITED's registered trademark portfolio includes well-known marks such as COPASURE and TRACESURE. These are among 2 currently registered trademarks in the portfolio.

What is ANIMAX LIMITED's trademark registration success rate?

ANIMAX LIMITED has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.